GlassScriptPhysician profile
Ted L Thompson
NPI 1083618722
$1,519.58
in general payments reported to CMS, 2019-2025
20 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.88 · 2020: $77.93 · 2021: $170 · 2022: $320 · 2023: $297 · 2024: $198 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.43 | 2020-2025 | Qulipta, Ubrelvy |
| Lundbeck LLC | $169.44 | 2024-2025 | Vyepti |
| Glaxosmithkline, LLC. | $155.08 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $151.31 | 2021-2023 | Farxiga |
| Novo Nordisk INC | $117.76 | 2021-2025 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $104.55 | 2019-2024 | Austedo Xr |
| Pfizer INC. | $102.57 | 2020-2024 | |
| Ultragenyx Pharmaceutical INC. | $55.83 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $36.97 | 2022-2023 | Xarelto |
| Lilly USA, LLC | $36.68 | 2023-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.96 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $34.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.15 | 2019-2020 | |
| Neurelis, INC. | $22.34 | 2023 | Valtoco |
| Alkermes, INC. | $22.27 | 2024 | Vivitrol |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.95 | 2024 | Caplyta |
| Merck Sharp & Dohme LLC | $19.05 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.76 | 2024 | Gvoke Hypopen |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.17 | 2022 | |
| Philips North America LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.